New fast test to diagnose bacterial endophthalmitis

Article

A newly-developed fast real-t PCR (f-real-t PCR) test is an effective and much more rapid way to diagnose bacterial endophthalmitis (BE), concluded a study published online ahead of print by the British Journal of Ophthalmology.

A newly-developed fast real-t PCR (f-real-t PCR) test is an effective and much more rapid way to diagnose bacterial endophthalmitis (BE), concluded a study published online ahead of print by the British Journal of Ophthalmology.

Pablo Goldschmidt, of the Laboratoire du Centre National d’Ophtalmologie des Quinze-Vingts, France, and colleagues examined specimens of vitreous fluid (VF) and aqueous humour (AH) cells from endophthalmitis, infected with bacteria or non-infective disorders and control to determine if the f-real-t PCR testing method they had developed could overcome the barriers most commonly associated with BE testing, including insufficient VF or AH, PCR cross-contamination and culture insensitivity, to identify the bacteria and Genera of the DNA that had been extracted from the specimen cells. The team compared the diagnoses with those from direct microscopic examination and culture.

The f-real-t PCR showed no cross-reactivity with fungi even though it detected ≥0.01 CFU Bac/µl and had a 100% correlation with culture positive results. Of the BE samples, 60% tested culture positive; with f-real-t PCR, this was 90%. Within 90 minutes, the f-real-t PCR detected and quantified the presence of Bac, Staphylococci, Streptococci, Haemophilus, Pseudomonas, Enterobacteria, Acinetobacter, Propionbacteriacae and Corynebacteria. The non-infective cells tested negative.

The team therefore concluded that their f-real-t PCR test reduced substantially the hours or even days required for cultures, and provided a more accurate result. The test’s developers now plan to run a larger series of samples to assess the utility of the test.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.